Marinus leaves the way clear for Sage
In the wake of a clinical trial failure Marinus plays down oral ganaxolone, but investors are unimpressed.
Upcoming events – Sage duels with Marinus
Sage Therapeutics looks to keep up momentum with SAGE-217 in bipolar depression, while Marinus tries to catch up with an oral postpartum depression project.
